Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy
|ClinicalTrials.gov Identifier: NCT00897520|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : May 19, 2017
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer and predict how patients will respond to treatment.
PURPOSE: This research study is looking at biomarkers in patients with high-risk melanoma receiving high-dose interferon therapy.
|Condition or disease||Intervention/treatment|
|Melanoma (Skin)||Biological: recombinant interferon alfa Genetic: proteomic profiling Other: immunoenzyme technique Other: laboratory biomarker analysis|
- To screen serum specimens using a high throughput protein profiling platform that tests for the highest number of known biomarkers (detectable by antibodies) that could be predictors of response to interferon treatment, autoimmunity, and disease outcome in patients with high-risk melanoma undergoing high-dose interferon (IFNa2b) therapy .
- To compare soluble factors across all patients at each time point (baseline and during therapy).
- To compare pre-therapy vs post-therapy serum samples from these patients.
- To assess the kinetics of soluble factors' appearance, persistence, and disappearance during the 12 months of therapy.
- To assess whether the amount of specific soluble factors in the pre-therapy sample is predictive of response independent of therapy.
- To correlate statistically significant factors with S100 and autoimmunity in these patients.
- To confirm the data obtained with the Luminex technology.
OUTLINE: Patients are stratified according to survival (< 2 years vs > 5 years).
Blood samples collected from patients enrolled in E-1694 are analyzed using high throughput protein profiling by ELISA to compare changes in levels of putative biomarkers of interferon alfa-2b, including cytokines and paired receptors, chemokines, cell adhesion molecules, metalloproteinases, angiogenic markers, growth factors, soluble receptors, signal transduction molecules, hormones, and other biomarkers of disease and dysregulated immune processes, at baseline and during therapy.
|Study Type :||Observational|
|Actual Enrollment :||40 participants|
|Official Title:||PILOT-high Throughput-protein Profiling Analysis of Sera Collected From E1694 Patients Undergoing HDI (Arm B)|
|Actual Study Start Date :||January 14, 2008|
|Primary Completion Date :||January 24, 2010|
|Study Completion Date :||January 24, 2010|
- Serum sample screening via high throughput protein profiling in patients undergoing therapy [ Time Frame: 1 month ]
- Comparison of soluble factors [ Time Frame: 1 month ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00897520
|Study Chair:||Monica Panelli, PhD||University of Pittsburgh|